Portfolio prioritization
Multiple stakeholders from discovery, development, commercial have different views. Outside views, when sought, conflict with internal views.
Assessing in-licensing & investment opportunities
BD&L teams seek the outside view from those outside BD&L — stakeholders throughout the company. They also tap external relationships, but miss the diversity of larger networks.
Indication strategy choices
Which indications hold the most promise? Which are the quickest route to regulatory approval?
Protocol design
There are more analytics-based approaches all the time, leveraging machine learning to assess the impact of inclusion/exclusion criteria on success. Diverse expertise is critical to assess what the analytics say.
Sales Forecasting
Assessing the commercial potential of a new drug is an area where machine learning on its own provides almost no insight. Collective intelligence can really shine here.